Dopaminergic activities in the human striatum: Rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine

Neuroscience

Volumn 90, Issue 2, 1999, Pages 433-445

  Piggott, M A ^a   Marshall, E F ^b   Thomas, N ^a   Lloyd, S ^a   Court, J A ^a   Jaros, E ^a   Costa, D ^c   Perry, R H ^a   Perry, E K ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dementia; Dopamine receptors; Dopamine turnover; Human striatum; Imaging; Parkinson's disease

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR;

ARTICLE; BRAIN REGION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN TISSUE; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR DENSITY;

EID: 0032903140     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00465-5     Document Type: Article

References (67)

1. Alexander G.M., Schwartzman R.J., Brainard L., Gordon S.W., Grothusen J.R. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP Parkinsonism in monkeys. Brain Res. 588:1992;261-269.
2. 11C]raclopride. Mov. Disord. 12:1997;33-38.
3. Antonini A., Vontobel P., Psylla M., Gunther I., Maguire P.R., Missimer J., Leenders K.L. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Archs Neurol. 52:1995;1183-1190.
4. Arai H., Kosaka K., Iizuka R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J. Neurochem. 43:1984;388-393.
5. 123I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J. neural Transm., Suppl. 50:1997;9-24.
6. Camps M., Cortes R., Gueye B., Probst A., Palacios J.M. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience. 28:1989;275-290.
7. Camps M., Kelly P.H., Palacios J.M. Autoradiographic localization of dopamine D 1 and D 2 receptors in the brain of several mammalian species. J. neural Transm., Gen. Sect. 80:1990;105-127.
8. 3H]N-n-propylnorapomorphine. Brain Res. 375:1986;135-149.
9. Carlsson A., Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J. neural Transm. 38:1976;271-276.
10. Cortes R., Gueye B., Pazos A., Probst A., Palacios J.M. Dopamine receptors in human brain: autoradiographic distribution of D1 sites. Neuroscience. 28:1989;263-273.
11. 3H]Raclopride binding to brain tissue from subjects with schizophrenia: methodological aspects. Neuropharmacology. 36:1997;779-786.
12. De Keyser J. Subtypes and localization of dopamine receptors in human brain. Neurochem. Int. 22:1993;83-93.
13. De Keyser J., Ebinger G., Vauquelin G. Age-related changes in the human nigrostriatal dopaminergic system. Ann. Neurol. 27:1990;157-161.
14. De Keyser J., Ebinger G., Vauquelin G. D1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease. Archs Neurol. 47:1990;761-763.
15. 3H]mazindol autoradiography. J. comp. Neurol. 304:1991;419-434.
16. 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur. J. Nucl. Med. 24:1997;320-325.
17. Graham W.C., Clarke C.E., Boyce S., Sambrook M.A., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-Parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 514:1990;103-110.
18. Graham W.C., Sambrook M.A., Crossman A.R. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced Parkinsonism. Brain Res. 602:1993;290-303.
19. Groppetti A., Algeri S., Cattabeni F., Di Giulio A.M., Galli C.L., Ponzio F., Spano P.F. Changes in specific activity of dopamine metabolites as evidence of a multiple compartmentation of dopamine in striatal neurons. J. Neurochem. 28:1977;193-197.
20. Gurevich E.V., Bordelon Y., Shapiro R.M., Arnold S.E., Gur R.E., Joyce J.N. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Archs gen. Psychiat. 54:1997;225-232.
21. Guttman M. Receptors in the basal ganglia. Can. J. neurol. Sci. 14:1987;395-401.
22. Hall H., Sedvall G., Magnusson O., Kopp J., Halldin C., Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology. 11:1994;245-256.
23. 3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res. 648:1994;222-228.
24. Hersch S.M., Yi H., Heilman C.J., Edwards R.H., Levey A.I. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J. comp. Neurol. 388:1997;211-227.
25. Hietala J., Syvalahti E. Dopamine in schizophrenia. Ann. Med. 28:1996;557-561.
26. Joyce J.N., Lexow N., Bird E., Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse. 2:1988;546-557.
27. 125I]RTI-55. Synapse. 12:1992;99-111.
28. Kinnear P. R. and Grey C. D. (1994) SPSS for Windows Made Simple. Psychology Press.
29. Kish S.J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. New Engl. J. Med. 318:1988;876-880.
30. Kish S.J., Shannak K., Rajput A., Deck J.H., Hornykiewicz O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58:1992;642-648.
31. 3H]raclopride. Neurosci. Lett. 66:1986;85-90.
32. Kontur P.J., al-Tikriti M., Innis R.B., Roth R.H. Postmortem stability of monoamines, their metabolites, and receptor binding in rat brain regions. J. Neurochem. 62:1994;282-290.
33. Kopin I.J. The pharmacology of Parkinson's disease therapy: an update. A. Rev. Pharmac. Toxic. 32:1993;467-495.
34. Landwehrmeyer B., Mengod G., Palacios J.M. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res. molec. Brain Res. 18:1993;187-192.
35. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. natn. Acad. Sci. U.S.A. 93:1996;9235-9240.
36. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmac. Rev. 49:1997;231-252.
37. 3H]quinpirole: identification of a discrete population of putative D3 receptors. Synapse. 14:1993;90-95.
38. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. natn. Acad. Sci. U.S.A. 89:1992;8155-8159.
39. Levesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. natn. Acad. Sci. U.S.A. 92:1995;1719-1723.
40. Lewis S. W. (1996) Functional brain imaging. In Brain Imaging in Psychiatry (eds Lewis S. and Higgins N.), pp. 108-115. Blackwell Science, Oxford.
41. Madras B.K., Kaufman M.J. Cocaine accumulates in dopamine-rich regions of primate brain after i.v. administration: comparison with mazindol distribution. Synapse. 18:1994;261-275.
42. Malmberg A., Jackson D.M., Eriksson A., Mohell N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Molec. Pharmac. 43:1993;749-754.
43. Marshall E.F., Perry E.K., Perry R.H., McKeith I.G., Fairbairn A.F., Thompson P. Dopamine metabolism in post-mortem caudate nucleus in neurodegenerative disorders. Neurosci. Res. Commun. 14:1994;17-25.
44. Moratalla R., Quinn B., DeLanney L., Irwin I., Langston J.W., Graybiel A.M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. natn. Acad. Sci. U.S.A. 89:1992;3859-3863.
45. 2 receptors to mesostriatal regions of human forebrain. Proc. natn. Acad. Sci. U.S.A. 91:1994;11271-11275.
46. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottleib G.L., Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with Parkinsonism. Ann. Neurol. 37:1995;300-312.
47. Nyberg S., Farde L., Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate - Preliminary findings. Archs gen. Psychiat. 54:1997;953-958.
48. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 13:1990;254-258.
49. Perry E., Court J., Goodchild R., Griffiths M., Jaros E., Johnson M., Lloyd S., Piggott M., Spurden D., Ballard C., McKeith I., Perry R. Clinical neurochemistry: developments in dementia research based on brain bank material. J. neural Transm. 000:1998;000-000.
50. Perry E.K., Marshall E., Perry R.H., Irving D., Smith C.J., Blessed G., Fairbairn A.F. Cholinergic and dopaminergic activities in senile dementia of Lewy body type. Alz. Dis. Ass. Disord. 4:1990;87-95.
51. Perry R. (1993) Coronal map of Brodmann areas in the human brain. In Neuropsychiatric Disorders (eds Roberts G. and Leigh P.), pp. 1-10. Wolfe, London.
52. Piggott M. A. and Marshall E. F. (1996) Neurochemical correlates of pathological and iatrogenic extrapyramidal symptoms. In Dementia with Lewy Bodies: Clinical, Pathological, and Treatment Issues (eds Perry R. H., McKeith I. G. and Perry E. K.), pp. 449-467. Cambridge University Press, Cambridge.
53. Piggott M.A., Perry E.K., McKeith I.G., Marshall E., Perry R.H. Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity [letter, corrected; published erratum appears in Lancet (1994) 7 May, 343(8906), 1170]. Lancet. 343:1994;1044-1045.
54. 3H]MK-801 binding in postmortem human cortex. J. Neurochem. 58:1992;1001-1008.
55. Rinne J.O. Muscarinic and dopaminergic receptors in the aging human brain. Brain Res. 404:1987;162-168.
56. Rioux L., Frohna P.A., Joyce J.N., Schneider J.S. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov. Disord. 12:1997;148-158.
57. Robertson H.A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci. 15:1992;201-206.
58. Samuels S.C., Katz I.R. Neuroleptic medicaton in elderly people. Curr. Opin. Psychiat. 7:1994;358-363.
59. 3H]SCH 23390. Brain Res. 375:1986;291-301.
60. Severson J.A., Marcusson J., Winblad B., Finch C.E. Age-correlated loss of dopaminergic binding sites in human basal ganglia. J. Neurochem. 39:1982;1623-1631.
61. 125I]RTI-121. Synapse. 21:1995;364-372.
62. Staley J.K., Hearn W.L., Ruttenber A.J., Wetli C.V., Mash D.C. High affinity cocaine recognition sites on the dopamine transporter are elevated in fatal cocaine overdose victims. J. Pharmac. exp. Ther. 271:1994;1678-1685.
63. Strange P.G. New insights into dopamine receptors in the central nervous system. Neurochem. Int. 22:1993;223-236.
64. Sunahara R. K., Seeman P., Van Tol H. H. and Niznik H. B. (1993) Dopamine receptors and antipsychotic drug response. Br. J. Psychiat., Suppl. 31-8.
65. Tranquart F., Le Bras F.H., de Toffol B., Autret A., Guilloteau D., Baulieu J.L. Progressive supranuclear paralysis. Quantification of dopamine D2 receptors using radionuclide tomography. Presse Medicale. 23:1994;1299-1300.
66. 123I-IBZM single photon emission computed tomography. Archs Neurol. 50:1993;513-516.
67. Waddington J.L., O'Boyle K.M. The D1 dopamine receptor and the search for its functional role: from neurochemistry to behaviour. Rev. Neurosci. 1:1987;157-184.